First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022
- PMID: 35167979
- PMCID: PMC9194534
- DOI: 10.1016/j.idnow.2022.02.003
First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022
Abstract
Objectives: We aimed to investigate the first Omicron cases detected in France in order to assess case characteristics and provide supporting information on the possible impact of this variant on the healthcare system.
Methods: A standardized questionnaire was used to collect information from confirmed and probable Omicron cases.
Results: Median age of 468 investigated cases was 35 years, 376 were symptomatic (89%); 64% were vaccinated with two doses and 7% had received three doses. Loss of smell and taste were reported by 8.3% and 9% of cases, respectively. Seven cases were hospitalized, three of those were unvaccinated (including two with reported precondition). No admissions to intensive care and no deaths were reported.
Conclusions: Our results confirm a mild clinical presentation among the first Omicron cases detected in France and highlight the importance for the national COVID-19 surveillance system to quickly detect and adapt to the emergence of a new variant.
Keywords: COVID-19; Epidemiology; SARS-CoV-2; Signs and symptoms; Surveys and questionnaires.
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Figures


Similar articles
-
Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021.J Med Virol. 2022 May;94(5):2290-2295. doi: 10.1002/jmv.27613. Epub 2022 Feb 3. J Med Virol. 2022. PMID: 35060146 Free PMC article.
-
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):177-181. doi: 10.15585/mmwr.mm7105e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35113851 Free PMC article.
-
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085222 Free PMC article.
-
Structural impact of a new spike Y170W mutation detected in early emerging SARS-CoV-2 Omicron variants in France.Virus Res. 2024 May;343:199354. doi: 10.1016/j.virusres.2024.199354. Epub 2024 Mar 16. Virus Res. 2024. PMID: 38492859 Free PMC article. Review.
-
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis.Expert Rev Vaccines. 2022 Dec;21(12):1831-1841. doi: 10.1080/14760584.2022.2130773. Epub 2022 Oct 14. Expert Rev Vaccines. 2022. PMID: 36242513
Cited by
-
A data set of symptoms and needs of individuals affected by COVID-19.Sci Data. 2024 Jan 24;11(1):122. doi: 10.1038/s41597-024-02961-6. Sci Data. 2024. PMID: 38267450 Free PMC article.
-
Evaluation of Analytical and Clinical Performance and Usefulness in a Real-Life Hospital Setting of Two in-House Real-Time RT-PCR Assays to Track SARS-CoV-2 Variants of Concern.Viruses. 2023 May 4;15(5):1115. doi: 10.3390/v15051115. Viruses. 2023. PMID: 37243201 Free PMC article.
-
Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024.Euro Surveill. 2025 Jan;30(1):2400293. doi: 10.2807/1560-7917.ES.2025.30.1.2400293. Euro Surveill. 2025. PMID: 39790077 Free PMC article.
-
Evaluating the impact of large-scale nucleic acid testing and home quarantine on a novel emerging infectious disease prevention and control: a dynamic modeling approach.Front Public Health. 2025 May 19;13:1447738. doi: 10.3389/fpubh.2025.1447738. eCollection 2025. Front Public Health. 2025. PMID: 40458103 Free PMC article.
-
Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis.Cells. 2023 Jan 28;12(3):430. doi: 10.3390/cells12030430. Cells. 2023. PMID: 36766771 Free PMC article.
References
-
- WHO . 2021. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Last accessed 22/01/2022. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.....
-
- Willett B.J., Grove J., MacLean O., Wilkie C., Logan N., De Lorenzo G., et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. medRxiv. 2022 [2022.01.03.21268111]
-
- WHO . 2021. Weekly epidemiological update on COVID-19-30 November 2021. Last accessed 22/01/2022. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on....
-
- Santé publique France . 2022. Consortium EMERGEN. [Available from: https://www.santepubliquefrance.fr/emergen.
-
- Grabowski F., Kochańczyk M., Lipniacki T. Omicron strain spreads with the doubling time of 3.2–3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. medRxiv. 2021 [2021.12.08.21267494]
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous